Skip to main content

Table 1 Baseline patient characteristics

From: The effect of denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element analysis

  n = 15
Age (years) 67.0 (65.0/75.5)
BMI (kg/m2) 23.0 (20.7/25.7)
Fracture, n (%) 9.0 (60.0)
History of family fracture, n (%) 1.0 (7.1)
Smoking, n (%) 0 (0)
Alcohol, n (%) 1.0 (6.7)
Albumin (mg/dL) 4.4 (4.3/4.4)
Calcium (mg/dL) 9.3 (9.2/9.6)
Phosphate (mg/dL) 3.6 (3.3/3.8)
Alkaline phosphatase (U/L) 301.0 (288.5/336.0)
eGFR (mL/min) 69.0 (62.0/90.0)
intact PTH (pg/mL) 35.0 (26.0/63.5)
Bone turnover markers
 total P1NP (μg/dL) 53.50 (40.00/91.60)
 TRACP-5b (mU/dL) 412.00 (385.50/581.50)
Areal BMD (g/cm2) measured by DXA
 Lumbar spine 0.70 (0.66/0.77)
 Femoral neck 0.56 (0.49/0.59)
 Total hip 0.70 (0.63/0.74)
Volumetric BMD (mg/cm3) measured by QCT
 Central-vBMD 56.90 (49.22/70.27)
 Right side of PS-vBMD 59.48 (52.94/82.25)
 Left side of PS-vBMD 60.33 (53.67/81.03)
  1. Data are expressed as median (Q1/Q3)
  2. BMI body mass index, eGFR estimate glomerular filtration, PTH parathyroid hormone, P1NP N-terminal propeptide of type 1 procollagen, TRACP-5b tartrate-resistant acid phosphatase 5b, BMD bone mineral density, DXA dual energy X-ray absorptiometry, QCT quantitative computed tomography, PS-vBMD pedicle screw volumetric bone mineral density
\